Search   
MSDS  : 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro -3,10,12,12a- tetrahydroxy-1,11-dioxo-, monohydrochloride
CAS  : 13614-98-7
SYNONYMS  : * Minocin * Minocyn * Minocycline chloride * Minocycline hydrochloride * Mynocine * Tri-mino * Tri-minocycline
*** CHEMICAL IDENTIFICATION ***

RTECS NUMBER : QI7630500
CHEMICAL NAME : 2-Naphthacenecarboxamide,
4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro
-3,10,12,12a- tetrahydroxy-1,11-dioxo-,
monohydrochloride
CAS REGISTRY NUMBER : 13614-98-7
LAST UPDATED : 199506
DATA ITEMS CITED : 16
MOLECULAR FORMULA : C23-H27-N3-O7.Cl-H
MOLECULAR WEIGHT : 493.99
WISWESSER LINE NOTATION : L E6 C666 BV FV GUTTT&J DQ EQ GVZ HQ IN1&1 ON1&1 LQ
&GH
COMPOUND DESCRIPTOR : Drug
Human
SYNONYMS/TRADE NAMES :
* Minocin
* Minocyn
* Minocycline chloride
* Minocycline hydrochloride
* Mynocine
* Tri-mino
* Tri-minocycline

*** HEALTH HAZARD DATA ***

** ACUTE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human
DOSE/DURATION : 14286 ug/kg/10D-I
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - respiratory obstruction
Lungs, Thorax, or Respiration - dyspnea
Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago,
IL 60610) V.1- 1908- Volume(issue)/page/year: 154,1633,1994

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - woman
DOSE/DURATION : 42 mg/kg/3W-I
TOXIC EFFECTS :
Blood - agranulocytosis
Blood - other changes
Musculoskeletal - joints
REFERENCE :
AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago,
IL 60610) V.1- 1908- Volume(issue)/page/year: 154,1983,1994

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - man
DOSE/DURATION : 3893 mg/kg/4Y-I
TOXIC EFFECTS :
Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
ARDEAC Archives of Dermatology. (AMA, 535 N. Dearborn St., Chicago, IL
60610) V.82- 1960- Volume(issue)/page/year: 122,17,1986

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - man
DOSE/DURATION : 11429 ug/kg/4D-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified
Skin and Appendages - dermatitis, other (after systemic exposure)
Nutritional and Gross Metabolic - body temperature increase
REFERENCE :
ARDEAC Archives of Dermatology. (AMA, 535 N. Dearborn St., Chicago, IL
60610) V.82- 1960- Volume(issue)/page/year: 123,18,1987

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Human - man
DOSE/DURATION : 2857 ug/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - fibrosis, focal (pneumoconiosis)
Lungs, Thorax, or Respiration - other changes
REFERENCE :
IEDIEP Internal Medicine. (The Japanese Society of Internal Medicine, 34-3,
3-chome, Hongo, Bunkyo-ku, Tokyo 113, Japan) V.31- 1992-
Volume(issue)/page/year: 33,177,1994

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 2380 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,811,1982

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 331 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,811,1982

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 1700 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho
Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970-
Volume(issue)/page/year: 21,319,1990

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 164 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,811,1982

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 3600 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,811,1982

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 299 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,811,1982

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 2290 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho
Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970-
Volume(issue)/page/year: 21,319,1990

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 154 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,811,1982

TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Parenteral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 620 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
CHTHBK Chemotherapy (Basel). (S. Karger Pub., Inc., 79 Fifth Ave., New
York, NY 10003) V.13- 1968- Volume(issue)/page/year: 24,17,1978

** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 280 mg/kg/4W-I
TOXIC EFFECTS :
Endocrine - changes in spleen weight
Blood - normocytic anemia
Blood - other changes
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu
Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972-
Volume(issue)/page/year: 16,2421,1988

*** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA ***

NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA :
NOES - National Occupational Exposure Survey (1983)
NOES Hazard Code - X4279
No. of Facilities: 105 (estimated)
No. of Industries: 1
No. of Occupations: 2
No. of Employees: 3012 (estimated)
No. of Female Employees: 1361 (estimated)


*** END OF RECORD ***
Search More   
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
NAMECAS
Myxovalargin A 82658-75-1
Myxovalargin B 85568-63-4
4-Morpholinepropanamine,N-(5-chloro-2-nitrobenzo(b)thien-3-yl)- 149338-22-7
Myxovalargin C 85568-64-5
Myxovalargin D 85568-65-6
Naematolin 11054-16-3
Nagase (bacillus subtilis) 11054-16-3
Najatoxin 11054-16-3
Named reagents and solutions, cpd 39374-34-0
4a-epi-Nanaomycin B 72691-97-5
Nandina domestica Thunb., stem extractSUBSTANCE DEFINITION :Plant containing berberine-type alkaloidsREFERENCE :YKKZAJ Yakugaku Zasshi. Journal of Pharmacy. (Nippon Yakugakkai, 2-12-15Shibuya, Shibuya-ku, Tokyo 150, Japan) No.1- 1881-Volume(issue)/page/year: 82,726,1962 72691-97-5
Naphth(2,3-a)aceanthrylene 84030-79-5
Naphthacene 92-24-0
4-Morpholinepropanamine,N-(3-chlorophenyl)-2,6-dimethyl-N-4-pyridinyl-,mono(2-hydroxybenzoate) 59235-63-1
2-Naphthacenecarboxamide,N-((4-(amidinoamidino)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-di oxo- 16545-11-2
2-Naphthacenecarboxamide,N-((4-(amidinoamidino)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-diox o-, dihydrochloride 13040-98-7
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo- 10118-90-8
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5a-alpha,12a-alpha))-,disulfate (1:2) (salt) 10118-90-8
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-,monohydrochloride 13614-98-7
2-Naphthacenecarboxamide,7-bromo-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10- 12,12a-pentahydroxy-6-methyl-1,11-dioxo- 4572-56-9
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,12a-decahydro-1,11-dioxo-N-(hydroxymethyl)-6-methyl-3,6,10,12,12a-pentahydroxy- 1181-54-0
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-1,11-dioxo- 127-33-3
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-1,11-dioxo-,monohydrochloride 64-73-3
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo- 57-62-5
4-Morpholinepropanamine,N-(3-chlorophenyl)-beta-methyl-N-4-pyridinyl-, (Z)-2-butenedioate (1:2) 21957-74-4
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 64-72-2
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo- 2013-58-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alpha))- 79-57-2
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-,calcium salt (1:1),(4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alpha))- 7179-50-2
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12, 12a-hexahydroxy-6-methyl-1,11-dioxo-,disodium deriv., dihydrate 6153-65-7
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-2,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,monohydrochloride, mixed with potassium nitrite 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-, compd.with sodium nitrite (1:3) 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-, sodiumsalt 69766-62-7
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12, 12a-hexahydroxy-6-methyl-1,11-dioxo-,sulfate 64038-91-1
4-Morpholinepropanamine,N-(3-chlorophenyl)-N-4-pyridinyl-,bis(2-hydroxybenzoate) 21928-15-4
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-N-((4-(2-hydroxyethyl)-1-piperazinyl)methyl)-6-methyl-1,11-di oxo- 1110-80-1
2-Naphthacenecarboxamide,4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,11,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dioxo- 564-25-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo- 60-54-8
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 10592-13-9
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 64-75-5
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)- 751-97-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-, mononitrate (salt) 20685-78-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5a-alpha,6-beta,12a-alpha))-,compd. with 4-hydroxy-3-methoxybenzenesulfonate (1:1) 20228-26-6
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo- 914-00-1
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a- pentahydroxy-6-methylene-1,11-dioxo-,monohydrochloride 3963-95-9
4-Morpholinepropanamine,N-(3-chlorophenyl)-N-4-pyridinyl-beta,2,6-trimethyl-,mono(2-hydroxybenzoate) 23410-76-6
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-9-(morpholinomethyl)-1,11-dioxo- 67238-91-9
2-Naphthacenecarboxamide,N,N'-(ethylenebis((methylimino)methylene))bis(4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-di oxo- 17910-68-8
2-Naphthacenecarboxamide,1,4,4a,5,12,12a-hexahydro-4-(dimethylamino)-1,12-dioxo-6-methyl- 3,10,11,12a-tetrahydroxy-,(4S-(4-alpha,4a-alpha,12a-alpha))- 1665-56-1

Free MSDS Search ( Providing 250,000+ Material Properties )
Chemcas.com| Ads link:todaystock.net